
    
      This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab
      combined with chemoradiotherapy for unresectable,locally advanced squamous cell lung cancer.

      All patients were planned to receive radical dose of chest radiation and concurrent
      chemotherapy of weekly docetaxel and cisplatin, each of 1 day's duration.

      Nimotuzumab group was treated with weekly nimotuzumab (200mg, IV) combined with
      chemoradiotherapy, while control group was treated with chemoradiotherapy.
    
  